Clinical trial
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory…
NCT00004862 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004862 |
|---|---|
| Title | Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| Official title | A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate |
| Enrollment | 24 |
| Start date | Oct 1, 1999 |
| Primary completion | Dec 1, 2001 |
| First posted | Jan 29, 2004 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: